Navigation Links
BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture

BioMarin will Continue to Manufacture; Genzyme will Continue to Market and

Sell Aldurazyme

NOVATO, Calif. and CAMBRIDGE, Mass., Jan. 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Genzyme Corporation (Nasdaq: GENZ) announced today a restructuring of their joint venture regarding Aldurazyme(R) (laronidase). Under the revised structure, the operational responsibilities for BioMarin and Genzyme will not significantly change. Genzyme will continue to globally market and sell Aldurazyme for mucopolysaccharidosis I (MPS I) and BioMarin will continue to manufacture Aldurazyme.

As of January 1, 2008, instead of sharing all costs and profits equally through the 50/50 joint venture, Genzyme will record sales of Aldurazyme and will pay BioMarin a tiered payment ranging from approximately 39.5 to 50 percent of worldwide net product sales, which will also be recorded by BioMarin as product revenue. Under the revised structure, payments are projected to result in both BioMarin and Genzyme receiving approximately the same profit as under the original joint venture structure. BioMarin will receive all of the benefits from increased manufacturing efficiencies and Genzyme will receive all of the benefits from increased commercialization efficiencies. Certain research and development activities related to Aldurazyme and intellectual property will continue to be managed in the joint venture on a 50/50 basis.

"This new structure provides both companies a better alignment of financial incentives with operational decisions and represents a more appropriate structure for two companies manufacturing and commercializing multiple products," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "This structure will also reduce management time and provide stronger incentives for each company to maximize the efficiency of its own operations related to Aldurazyme. Lastly, this new structure allows the companies to collaborate and equally share costs on research projects which could lead to important advances for MPS I patients."

About MPS I

MPS I is a rare, progressive, heterogeneous, debilitating disease caused by a deficiency of the enzyme alpha L-iduronidase that affects an estimated 3,000 to 4,000 people worldwide, including approximately 1,000 in the United States. Patients who lack this enzyme accumulate a carbohydrate called glycosaminoglycan (GAG) in tissues and organ systems. A majority of patients die before adulthood due to a wide range of problems related to the disease, including progressive damage to the heart, lungs, liver, and kidneys. Aldurazyme addresses the underlying cause of MPS I by replacing the missing enzyme through a weekly infusion. More information about MPS I can be found at

About Aldurazyme

Aldurazyme is indicated for patients with the Hurler and Hurler-Scheie forms of MPS I, and for Scheie patients with moderate to severe symptoms. The risks and benefits of treating mildly affected patients with the Scheie form have not been established. Aldurazyme has not been evaluated for effects on the central nervous system manifestations of the disorder. More information on Aldurazyme can be found at

The most common side effects associated with treatment with Aldurazyme were upper respiratory tract infection, rash, and injection site reaction. The most common adverse reactions requiring treatment were infusion-related hypersensitivity reactions including flushing, fever, headache, and rash. The most serious adverse reaction reported with Aldurazyme was an anaphylactic reaction consisting of hives and blockage of the breathing tubes, which occurred in one person. Emergency surgery was required to help this patient breathe. This patient's underlying disease may have contributed to the severity of this reaction. The majority of patients in clinical studies developed an immune response to treatment with Aldurazyme. The clinical significance of this response is unknown. Aldurazyme is available by prescription only. Full prescribing information is available at

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit Information on BioMarin's website is not incorporated by reference into this press release.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease and other areas of unmet medical need.

Forward-Looking Statement

This press release contains forward-looking statements, including without limitation statements about: expectations and plans related to the commercialization and manufacture of Aldurazyme; estimates concerning the MPS I patient population, and the anticipated benefits of the restructuring. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: the effectiveness of Genzyme's commercialization plan for Aldurazyme and Genzyme's sales force; BioMarin's ability to manufacture sufficient quantities of product and to do so in a timely and cost efficient manner; the accuracy of the companies' information concerning the MPS I patient population; the content and actual timing of decisions by regulatory authorities concerning marketing applications, labeling and pricing for Aldurazyme and manufacturing facilities to be used for Aldurazyme; the companies' ability to obtain and maintain adequate patent and other proprietary rights protection for Aldurazyme; and those factors detailed in BioMarin's and Genzyme's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual Report on Form 10-K, as amended, the factors contained in BioMarin's reports on Form 8-K, and the factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Neither BioMarin nor Genzyme is under any obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R) is a registered trademark of BioMarin Pharmaceutical Inc.

Genzyme(R) is a registered trademark of Genzyme Corporation.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

All rights reserved.


BioMarin Genzyme

Investors Investors

Eugenia Shen Sally Curley

(415) 506-6570 (617) 768-6140

Media Media

Susan Berg Maria Cantor

(415) 506-6594 (617) 768-6690

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
2. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
3. BioMarin to Present at the BioCentury NewsMakers Conference
4. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
5. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
6. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
7. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
8. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme Launches Cholestagel(R) in Europe
11. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
Post Your Comments:
(Date:10/8/2015)... 2015 The 2015 Nobel Prize in Chemistry ... at Dallas. Aziz Sancar , who earned his PhD ... in 1977, is one of three scientists who received the ... repair damaged DNA on a molecular level.  --> Aziz ... from UT Dallas in 1977, is one ...
(Date:10/8/2015)... -- Today the Wyss Institute for Biologically Inspired Engineering at ... Opsonix Inc. The announcement follows a worldwide ... Development (OTD) and Opsonix Inc. enabling the company ... --> --> ... year in the U.S. — more than prostate cancer, ...
(Date:10/8/2015)... (PRWEB) , ... October 08, 2015 , ... ... in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and results in dysfunction ... and sticky mucus accumulates in the lungs. This mucus is very difficult to ...
(Date:10/7/2015)... ... October 07, 2015 , ... ... ) will present a public educational seminar on the latest advances in adult ... from 1:00 pm – 3:00 pm at the Hilton Dallas/Southlake Town Square in ...
Breaking Biology Technology:
... , EAST GRINSTEAD, West Sussex, U.K. ... a Magellan Biosciences business and premier provider of ... has expanded its East Grinstead, U.K., manufacturing and ... demand for its Sensititre® product line for susceptibility ...
... , , MISSISSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - ... YM), a life sciences product development company that identifies ... at various stages of development, announced that results from ... poster at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer ...
... BONITA SPRINGS, Fla., Nov. 18 Algenol Biofuels LLC, ... group The Linde Group have agreed to collaborate in ... optimum management of carbon dioxide (CO2) and oxygen (O2) ... will see the companies join forces to develop cost-efficient ...
Cached Biology Technology:
(Date:10/7/2015)... -- NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet ... term executive at American Express has been appointed to ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... the Wocket® smart wallet announces Mr. Stanley E. ...
(Date:10/2/2015)... -- ) has announced ... Using Biometrics" report to their offering. ... of the "Enforcing the Law Using Biometrics" ... Research and Markets ( ) has announced ... Using Biometrics" report to their offering. ...
(Date:9/30/2015)... -- The global glucose monitoring device and diabetes management market is ... report on the industry from Kalorama Information. Sales in the traditional ... by continuous glucose monitoring and sensor segment, according to the ... products in its latest report, The Global Glucose Monitoring ... , ...
Breaking Biology News(10 mins):
... This release is available in German . ... NEEM (North Greenland Eemian Ice Drilling) in north-western Greenland was ... of the Alfred Wegener Institute for Polar and Marine Research ... altogether 1757.87 m length on the Greenland inland ice within ...
... scientists from Monash University have modified a human embryonic stem ... become red blood cells. The modified hESC line, ... of generating mature, fully functional red blood cells from human ... team led by Professors Andrew Elefanty and Ed Stanley at ...
... principal investigator of the Champalimaud Neuroscience Programme at the ... of only 219 recipients of the prestigious European Research ... 2009 edition of this flagship award scheme. The grant, ... of five years, will allow Rui Costa,s young research ...
Cached Biology News:
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The ProteoSpin CBED Micro Kit provides a ... exchange and desalting of protein samples. The ... Norgens patented protein resin as an ion ... CaCl2,LiCl, CsCl have poor affinities for Norgens ...
... ProteinChip beta-amyloid Multipeptide Kit, designed for ... detecting a variety of amyloid peptides ... before. - Clinical neuroscience proteomics applications ... treatment - Correlate beta-amyloid peptide levels ...
... Contents include: Microarray hybridization chamber ... chamber top, clamp, thumbscrew) Microarray chamber user ... and are intended to be cleaned and ... with Agilents Catalog Oligo Microarray kits and ...
Biology Products: